Cochrane · systematic review · CD009510
Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion
Shalchi, Z, Mahroo, O, Bunce, C, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
14
No studies
1
Included studies
NR
No studies 1 · 6.7%Ungraded 0 · 0%Very low 2 · 13.3%Low 0 · 0%Moderate 10 · 66.7%High 2 · 13.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Anti‐VEGF compared to sham for macular oedema secondary to branch retinal vein occlusion
Population: macular oedema secondary to branch retinal vein occlusion
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Gain of 15 letters or more of visual acuity at 6 months Anti‐VEGF vs sham | RR 1.72 [1.19, 2.49] | 1 study · 283 participants | Moderate Downgraded: risk of bias |
Mean change in visual acuity letters at 6 months Anti‐VEGF vs sham | no estimate extracted | 1 study · 282 participants | Moderate Downgraded: risk of bias |
Mean central retinal thickness (CRT) change at 6 months in microns (lower value is better) Anti‐VEGF vs sham | no estimate extracted | 1 study · 281 participants | Moderate Downgraded: risk of bias |
Adverse outcomes at any time point Anti‐VEGF vs sham | RR 0.98 [0.09, 10.66] | 1 study · 283 participants | Very low Downgraded: risk of bias, imprecision |
Mean change in quality of life (QoL) at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100) (higher score is better quality of life) Anti‐VEGF vs sham | no estimate extracted | 1 study · 281 participants | Moderate Downgraded: risk of bias |
Anti‐VEGF compared to laser for branch retinal vein occlusion (BRVO)
Population: people with BRVO
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Gain of 15 letters or more of visual acuity Anti‐VEGF vs laser | RR 2.09 [1.44, 3.05] | 2 studies · 201 participants | Moderate Downgraded: risk of bias |
Mean change in visual acuity letters Anti‐VEGF vs laser | no estimate extracted | 3 studies · 473 participants | Moderate Downgraded: risk of bias |
Mean central retinal thickness (CRT) change at 6 months in microns (lower value is better) Anti‐VEGF vs laser | no estimate extracted | 2 studies · 201 participants | Moderate Downgraded: risk of bias |
Adverse outcomes at any time point Anti‐VEGF vs laser | RR 2.97 [0.12, 71.89] | 2 studies · 456 participants | Very low Downgraded: risk of bias, imprecision |
Mean change in quality of life at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100) (higher score is better quality of life) Anti‐VEGF vs laser | no estimate extracted | NR | No studies |
Anti‐VEGF compared to steroid for branch retinal vein occlusion (BRVO)
Population: people with BRVO
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Gain of 15 letters or more of visual acuity Anti‐VEGF vs steroid | RR 1.67 [1.33, 2.1] | 2 studies · 330 participants | High |
Mean change in visual acuity letters Anti‐VEGF vs steroid | no estimate extracted | 2 studies · 330 participants | High |
Mean central retinal thickness (CRT) change at 12 months in microns (lower value is better) Anti‐VEGF vs steroid | no estimate extracted | 2 studies · 343 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse outcomes at any time point Anti‐VEGF vs steroid | RR 0.12 [0.04, 0.32] | 3 studies · 551 participants | Moderate Downgraded: risk of bias, imprecision |
Mean change in quality of life at 12 months on the National Eye Institute Visual Functioning Questionnaire‐25 (VFQ‐25) (scored 0 to 100) (higher score is better quality of life) Anti‐VEGF vs steroid | no estimate extracted | 1 study · 307 participants | Moderate Downgraded: risk of bias, imprecision |